Business · 1 sources covering this

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·2h ago
A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/61b03216de88f7727db6399a2738cc160907ba5e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled"></iframe>

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

How 1 sources are covering this

A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled

More from Business

Drivers may get compensation offers before car finance saga ends

Midterm elections could jolt stocks if Democrats sweep Congress

Proposal for free bus service scrapped

UK and EU agree draft deal to scrap Brexit red tape over food exports

Reader

Trust & legal

Across the network